Payment overview · 2025
General Payments
$53,070.81
137 reported records · 18 companies
Healthcare provider profile · identity verified
Johnathon Curtis Rollo, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · LOS ANGELES, CA · NPI 1104185644
Verified facts
What the public records show
CMS Open Payments records show Johnathon Curtis Rollo, MD received $53,070.81 in general payments during 2025 across 137 reported records.
Shockwave Medical, Inc accounted for 59.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $31,425.93 | 59.2% | 18 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17,058.63 | 32.1% | 61 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $1,121.08 | 2.1% | 9 | 2025 |
| Balt USA, LLC | Unresolved — no canonical attribution shown | $791.79 | 1.5% | 9 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $370.31 | 0.7% | 6 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $369.42 | 0.7% | 4 | 2025 |
| Shape Memory Medical Inc. | Unresolved — no canonical attribution shown | $347.37 | 0.7% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$344.27 | 0.7% | 10 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $276.68 | 0.5% | 3 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $261.40 | 0.5% | 4 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $225.02 | 0.4% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $129.70 | 0.2% | 2 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $102.51 | 0.2% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $90.52 | 0.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $86.90 | 0.2% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $27.68 | 0.1% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $25.25 | 0.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $16.35 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $27,250.00 | 10 |
| Travel and Lodging | $14,665.29 | 32 |
| Food and Beverage | $11,155.52 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $31,425.93 | 18 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $9,602.57 | 35 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $3,397.70 | 12 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $2,098.94 | 11 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $1,750.00 | 1 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $1,121.08 | 9 | 2025 |
Source payment records
|
|||||
| Prestige Coil System Normalized: prestige coil system |
Device | Balt USA, LLC | $721.41 | 7 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $370.31 | 6 | 2025 |
Source payment records
|
|||||
| IMPEDE EMBOLIZATION PLUG Normalized: impede embolization plug |
Device | Shape Memory Medical Inc. | $347.37 | 3 | 2025 |
Source payment records
|
|||||
| ZENITH ALPHA Normalized: zenith alpha |
Device | Cook Medical LLC | $339.23 | 2 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $274.12 | 6 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $242.98 | 2 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $139.48 | 1 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $137.00 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $106.28 | 1 | 2025 |
Source payment records
|
|||||
| XACT Normalized: xact |
Device | Abbott Laboratories | $103.14 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $102.51 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $102.51 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $90.52 | 1 | 2025 |
Source payment records
|
|||||
| RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Normalized: relay thoracic stent graft with plus delivery system |
Device | Bolton Medical Inc | $89.66 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $88.02 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $86.90 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $84.65 | 1 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $80.09 | 2 | 2025 |
Source payment records
|
|||||
| Revere Hybrid Access Catheter Normalized: revere hybrid access catheter |
Device | Balt USA, LLC | $70.38 | 2 | 2025 |
Source payment records
|
|||||
| MICRO ACCESS Normalized: micro access |
Device | AngioDynamics, Inc. | $45.05 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $41.83 | 1 | 2025 |
Source payment records
|
|||||
| ROSEN Normalized: rosen |
Device | Cook Medical LLC | $30.19 | 2 | 2025 |
Source payment records
|
|||||
| CLOSUREFAST Normalized: closurefast |
Device | Medtronic, Inc. | $25.73 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| VALIANT CAPTIVIA Normalized: valiant captivia |
Device | Medtronic, Inc. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX PL Normalized: stravix pl |
Biological | Smith+Nephew, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $6.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 25 | 16 |
| Cilostazol | Cilostazol | 16 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53,070.81 · 137 records | Shockwave Medical, Inc | AURYON LASER SYSTEM 100-120 VAC, Barostim Neo System, CGuard Prime Carotid Stent System, CLOSUREFAST, ENDOCROSS Device, ENDURANT IIS, ESPRIT, EXCLUDER Conformable AAA Endoprosthesis with Active Control, Flexitouch Plus, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE VIABAHN Endoprosthesis with Heparin, HAWKONE, IMPEDE EMBOLIZATION PLUG, IN.PACT ADMIRAL, Indigo System, MICRO ACCESS, Nimbl, PERCLOSE PROGLIDE, PERCLOSE PROSTYLE, Penumbra System, Prestige Coil System, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM, ROSEN, Revere Hybrid Access Catheter, STRAVIX PL, SUPERA, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TREO ABDOMINAL STENT-GRAFT SYSTEM, Torus Stent Graft System, VALIANT CAPTIVIA, Varithena Administration Pack, XACT, XIENCE SKYPOINT, ZENITH ALPHA, bio-ConneKt | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error